Arix Bioscience plc announced the establishment of a Scientific Advisory Board (“SAB”) and Board Investment Committee (“BIC”). The newly formed SAB will be chaired by Arix Non-Executive Director Professor Trevor Jones, CBE, FMedSci, and is comprised of leading researchers and industry executives dedicated to improving treatments for patients. The SAB will be primarily responsible for advising the Management Investment Committee and the newly formed Board Investment Committee regarding priority investment decisions. These changes are designed to provide access to specialist insight as Arix’s portfolio matures and new investment opportunities are evaluated. Joining the SAB are: Ruth Atherton, PhD, JD, executive sponsor of the Bill & Melinda Gates Foundation Global Access Team, leading development and implementation of the foundation’s intellectual property strategy; Andreas Busch, PhD, former Head of Research & Development and Chief Scientific Officer at Shire Pharmaceuticals; Professor Trevor Jones, CBE, FMedSci, current Arix Non-Executive Director, former Group R&D director at The Wellcome Foundation Limited; and Professor KJ Patel, FRS, FMedSci, Director of the MRC Weatherall Institute of Molecular Medicine and MRC Molecular Haematology Unit in Oxford. Finally, the creation of a Board Investment Committee will enable the Board to review and approve significant investment or disposal decisions. These changes will ensure greater engagement and oversight by the Board in management team decision making and build on the Board of Directors and executive leadership changes announced on 6 April 2020. The Board Investment Committee will be chaired by Naseem Amin, Executive Chairman, and include two non-executive directors. Following the AGM, the Board also intends to strengthen corporate governance with the appointment of a Senior Independent Director, in accordance with the UK Corporate Governance Code. The SAB and BIC formation, and any new future appointments to the Board of Directors, will be made in-line with strategic priorities and new operating cost structure.